undamentalytics Newsletter

Schuth Alexander O.: insider trades

Officer at Denali Therapeutics Inc. No open-market purchases and 20 sales not made under a pre-set plan, reported from April 1, 2020 to August 13, 2026.

What happened after Schuth Alexander O.’s sales?

After their sales, the shares moved −22.8% against the index over 12 months on average (a negative figure means selling was the right call); 89% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Schuth Alexander O.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 19 −10.0% −18.3% 68% 7 −0.44 0.68 No reliable evidence
Sales, 12 months after the report 18 −22.8% −31.5% 89% 6 0.05 0.96 No reliable evidence
Sales, 12 months after the trade 18 −25.0% −30.0% 89% 6 −0.12 0.91 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Denali Therapeutics Inc. DNLI COFO and Secretary020April 1, 2020August 13, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 13, 2026August 11, 2026 DNLI Sale $71,625 not yetnot yetnot yet
January 8, 2026January 6, 2026 DNLI Sale $284,097 +14.6%not yetnot yet
August 14, 2025August 12, 2025 DNLI Sale $39,884 +11.9%+44.8%+65.4%
January 8, 2025January 6, 2025 DNLI Sale $308,291 −25.8%−26.1%−31.0%
August 15, 2024August 13, 2024 DNLI Sale $52,006 +16.2%−53.5%−56.3%
January 9, 2024January 5, 2024 DNLI Sale $193,756 −7.0%−19.3%−17.9%
August 23, 2023August 21, 2023 DNLI Sale $55,978 −23.4%−15.5%−22.0%
August 14, 2023August 10, 2023 DNLI Sale $68,986 −33.0%−29.2%−28.4%
February 15, 2023February 13, 2023 DNLI Sale $105,225 −0.4%−67.6%−63.3%
February 10, 2023February 8, 2023 DNLI Sale $46,984 +5.6%−63.3%−64.7%
January 9, 2023January 5, 2023 DNLI Sale $74,968 −19.1%−57.3%−56.2%
January 5, 2023January 4, 2023 DNLI Sale $83,574 −22.6%−55.6%−56.9%
August 23, 2022August 19, 2022 DNLI Sale $85,575 +0.7%−33.9%−35.5%
February 15, 2022February 11, 2022 DNLI Sale $97,208 −22.4%−6.3%−9.4%
February 11, 2022February 9, 2022 DNLI Sale $52,793 −24.7%−9.0%−14.7%
January 7, 2022January 5, 2022 DNLI Sale $127,415 −20.5%−17.9%−19.4%
August 23, 2021August 19, 2021 DNLI Sale $126,186 −18.3%−34.5%−29.0%
February 16, 2021February 11, 2021 DNLI Sale $214,345 −16.9%−58.5%−64.4%
February 11, 2021February 9, 2021 DNLI Sale $109,811 −26.6%−62.1%−67.6%
April 1, 2020March 30, 2020 DNLI Sale $27,812 +21.4%+153.7%+121.9%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Schuth Alexander O. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.